GlassScriptPhysician profile
Sandeep Singh
NPI 1902203482
$10,650.52
in general payments reported to CMS, 2019-2025
57 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.13 · 2021: $785 · 2022: $2,561 · 2023: $3,145 · 2024: $2,426 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,646 · Education: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,646.25 |
| Education | $622.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $912.39 | 2021-2025 | Tecvayli, Rybrevant, Darzalex |
| Astellas Pharma US INC | $818.99 | 2021-2025 | Xtandi, Xospata, Vyloy |
| Astrazeneca Pharmaceuticals LP | $744.36 | 2021-2025 | Enhertu, Lynparza, Onglyza |
| Celgene Corporation | $560.44 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $529.58 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $511.37 | 2021-2025 | |
| Genzyme Corporation | $490.19 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $468.03 | 2020-2025 | Opdivo, Opdualag |
| Incyte Corporation | $465.26 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $367.47 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $305.78 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $303.78 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $206.68 | 2020-2022 | |
| Coherus Oncology, INC. | $206.08 | 2021-2024 | |
| Genentech USA, INC. | $201.62 | 2022-2025 | Venclexta, Polivy, Tecentriq |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $200.67 | 2021-2025 | Cabometyx |
| Beigene USA, INC. | $198.38 | 2021-2024 | Brukinsa |
| Seagen INC. | $173.32 | 2022-2023 | Adcetris, Tukysa |
| Emd Serono, INC. | $170.81 | 2021-2024 | Bavencio |
| Myriad Genetic Laboratories, INC. | $162.60 | 2023-2024 | Precisetumor, Myrisk |
| Regeneron Healthcare Solutions, INC. | $159.09 | 2022-2025 | Libtayo |
| Abbott Laboratories | $149.54 | 2024 | |
| Eisai INC. | $147.19 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $139.16 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Puma Biotechnology, INC. | $137.03 | 2021-2025 | Nerlynx |
| Karyopharm Therapeutics INC. | $134.56 | 2022-2025 | Xpovio |
| Glaxosmithkline, LLC. | $128.32 | 2022-2024 | Ojjaara, Jemperli, Zejula |
| Deciphera Pharmaceuticals INC. | $119.59 | 2021-2023 | Qinlock |
| G1 Therapeutics, INC. | $118.81 | 2022-2023 | Cosela |
| Adc Therapeutics America, INC. | $115.66 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.57 | 2022-2025 | Vpriv, Fruzaqla, Iclusig |
| Gilead Sciences, INC. | $102.19 | 2023-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $84.30 | 2023-2025 | Monoferric, Cosela |
| Adaptive Biotechnologies Corporation | $81.24 | 2023-2025 | Clonoseq |
| Progenics Pharmaceuticals, INC. | $79.61 | 2022-2023 | Pylarify |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| Taiho Oncology, INC. | $64.76 | 2022-2024 | |
| Global Blood Therapeutics, INC. | $63.45 | 2021-2022 | |
| Tersera Therapeutics LLC | $59.02 | 2022-2023 | Zoladex |
| Kite Pharma, INC. | $54.52 | 2025 | Yescarta |
| Alexion Pharmaceuticals, INC. | $53.08 | 2022-2024 | Ultomiris |
| Lilly USA, LLC | $52.90 | 2021-2025 | Verzenio, Jaypirca |
| Ipsen Biopharmaceuticals, INC | $51.85 | 2021-2022 | |
| Stemline Therapeutics INC. | $47.90 | 2023-2025 | Orserdu |
| Octapharma USA, INC. | $43.32 | 2023 | Panzyga |
| Sanofi US Services INC. | $34.90 | 2025 | |
| Morphosys, US INC. | $33.77 | 2021 | |
| Sobi, INC | $33.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.16 | 2022-2023 | Xarelto |
| Mirati Therapeutics, INC. | $25.29 | 2024 | Krazati |
| Dendreon Pharmaceuticals LLC | $24.73 | 2025 | Provenge |
| Foundation Medicine, INC. | $23.62 | 2023 | |
| Array Biopharma INC | $17.75 | 2025 | Braftovi, Mektovi, Tukysa |
| Epizyme, INC. | $17.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.08 | 2021 | |
| Dova Pharmaceuticals | $16.79 | 2021 | |
| Genmab U.S., INC. | $14.86 | 2023 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.